TATA-box binding protein associated factor 7Genealiases: TAF2F · TAFII55
Q-omics provides the consensus-scored TAF7 profile across patient tissues and cancer cell-line models. TAF7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TAF7 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TAF7 protein abundance shows 20,609 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, and GBM as cancer lineages where TAF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF7 survival associations across molecular data types. TAF7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF7 RNA expression–survival associations across cancer types. High TAF7 expression shows unfavorable associations in HNSC, UVM and KIRP, but favorable associations in KIRC, MESO and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TAF7 RNA expression.
This table summarizes TAF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TAF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF7 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, KIRP, KIRC and CHOL. The HNSC box plot shows higher TAF7 RNA expression in tumor versus normal tissue (log2 FC = +0.412, t-test p = .001).
This table shows molecular features associated with TAF7 in patient tissues and cancer cell lines. In patient samples, TAF7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
